Partners in Health
Quick facts
Marketed products
- sofosbubir/velpatasvir · Virology/Hepatology
Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication. - sofosbubir/velpatasvir/voxilaprevir · Infectious Disease / Virology
This combination inhibits three different hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: